HomeAI · summaries
Storia in 2 fonti
In latest twist in Zepzelca saga, Jazz and PharmaMar lung cancer drug fails phase 3 test
The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer (SCLC) drug Zepzelca may once again be in jeopardy. | The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer drug Zepzelca may once again be in jeopardy after another phase 3 failure.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
- ·
fiercepharma.com
In latest twist in Zepzelca saga, Jazz and PharmaMar lung cancer drug fails phase 3 test
The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer (SCLC) drug Zepzelca may once again be in jeopardy. | The accelerated approval for Jazz Pharmaceuticals’…